You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
通化東寶(600867.SH):三靶點抑制劑產品(THDBH101)臨牀申報獲批
格隆匯 06-28 15:53

格隆匯6月28日丨通化東寶(600867.SH)宣佈,公司全資子公司東寶紫星(杭州)生物醫藥有限公司(簡稱“東寶紫星”)申報的三靶點抑制劑(THDBH101膠囊/WXSHC071膠囊)(受理號CXHL2101065、CXHL2101066、CXHL2101067)藥品註冊申請,於近日收到國家藥監局核准簽發的藥物臨牀試驗批准通知書。

東寶紫星的三靶點抑制劑(SGLT1/SGLT2/DPP4)是全球首個將此三靶點結合的治療2型糖尿病產品,該產品在SGLT2作用機制的基礎上,通過SGLT1和DPP4的協同作用,藉助SGLT1在腸道調節葡萄糖吸收的作用進一步加強降糖效應,同時引入DPP4在降糖以及心血管、腎臟、肝臟等方面的保護作用,起到多種作用機制發揮疊加效果的作用,建立除降糖以外的臨牀獲益基礎。該產品目前尚無同類品種上市,亦無同類產品銷售數據。

截至搞公吿日,公司在該項目中已投入研發費用人民幣約2527萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account